RecruitingPhase 4NCT05593055

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension


Sponsor

Brigham and Women's Hospital

Enrollment

75 participants

Start Date

Aug 25, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how a hormone system called the mineralocorticoid receptor affects heart and blood vessel function in people with high blood pressure and an enlarged heart muscle (left ventricular hypertrophy). Researchers aim to understand the underlying biology to develop better treatments. **You may be eligible if...** - You have high blood pressure (whether or not you are on medication) - An echocardiogram (heart ultrasound) shows your heart muscle is thickened (left ventricular hypertrophy) - You may also have treated hypothyroidism, pre-diabetes, or diabetes managed without medications (except metformin) **You may NOT be eligible if...** - You have taken certain blood pressure medications (spironolactone, eplerenone, finerenone, or amiloride) in the past year - You have low blood pressure when standing (orthostatic hypotension) - You have significantly reduced heart pumping function (ejection fraction below 40%) - You have severe heart failure (Class III–IV) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEplerenone

After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.

DRUGChlorthalidone

After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.

DRUGPotassium

After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.


Locations(1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05593055


Related Trials